BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14(1): 1-14 [PMID: 18176955 DOI: 10.3748/wjg.14.1] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Le TBU, Vu TC, Ho RZW, Prawira A, Wang L, Goh BC, Huynh H. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E9405. [PMID: 33321903 DOI: 10.3390/ijms21249405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG, Evert M, Calvisi DF, Dombrowski F. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. Int J Mol Sci 2016;17:E1618. [PMID: 27669229 DOI: 10.3390/ijms17101618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Li C, Ge M, Yin Y, Luo M, Chen D. Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells. Mol Cell Biochem. 2012; Aug 7. [Epub ahead of print]. [PMID: 22868929 DOI: 10.1007/s11010-012-1404-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
4 Li H, Ren Z, Kang X, Zhang L, Li X, Wang Y, Xue T, Shen Y, Liu Y. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer 2009;9:366. [PMID: 19835603 DOI: 10.1186/1471-2407-9-366] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
5 Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012;1:11. [PMID: 23210562 DOI: 10.1186/2162-3619-1-11] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
6 Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol. 2014;6:716-737. [PMID: 25349643 DOI: 10.4254/wjh.v6.i10.716] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
7 Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;12:1347-57. [DOI: 10.1586/era.12.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
8 Wang TH, Ng KF, Yeh TS, Wang YL, Liang KH, Yeh CT, Chen TC. Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinoma. PLoS One 2012;7:e41749. [PMID: 22860012 DOI: 10.1371/journal.pone.0041749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis. 2011;29:289-302. [PMID: 21829020 DOI: 10.1159/000327562] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
10 Zhao M, He HW, Sun HX, Ren KH, Shao RG. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochem Biophys Res Commun. 2009;387:239-244. [PMID: 19563783 DOI: 10.1016/j.bbrc.2009.06.128] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
11 Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science 2009;100:1-8. [DOI: 10.1111/j.1349-7006.2008.01006.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
12 Pries AR, Cornelissen AJ, Sloot AA, Hinkeldey M, Dreher MR, Höpfner M, Dewhirst MW, Secomb TW. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 2009;5:e1000394. [PMID: 19478883 DOI: 10.1371/journal.pcbi.1000394] [Cited by in Crossref: 107] [Cited by in F6Publishing: 91] [Article Influence: 8.9] [Reference Citation Analysis]
13 Chen L, Shi Y, Jiang CY, Wei LX, Lv YL, Wang YL, Dai GH. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers. 2011;26:108-116. [PMID: 21574155 DOI: 10.5301/jbm.2011.8322] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
14 Mizuguchi Y, Takizawa T, Uchida E. Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication. World J Hepatol. 2015;7:696-702. [PMID: 25866606 DOI: 10.4254/wjh.v7.i4.696] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
15 Teng CF, Wu HC, Shyu WC, Jeng LB, Su IJ. Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cell Transplant 2017;26:429-38. [PMID: 28195035 DOI: 10.3727/096368916X694382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
16 Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci. 2009;1155:206-221. [PMID: 19250206 DOI: 10.1111/j.1749-6632.2009.03704.x] [Cited by in Crossref: 266] [Cited by in F6Publishing: 235] [Article Influence: 22.2] [Reference Citation Analysis]
17 Zhao Y, Gao Q, Pei L, Wang C, Jin L, Liao F. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. Int J Biol Markers 2017;32:361-9. [DOI: 10.5301/ijbm.5000299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Nitzsche B, Gloesenkamp C, Schrader M, Ocker M, Preissner R, Lein M, Zakrzewicz A, Hoffmann B, Höpfner M. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer 2010;103:18-28. [PMID: 20551952 DOI: 10.1038/sj.bjc.6605725] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
19 Friedman Ohana R, Hurst R, Rosenblatt M, Levin S, Machleidt T, Kirkland TA, Encell LP, Robers MB, Wood KV. Utilizing a Simple Method for Stoichiometric Protein Labeling to Quantify Antibody Blockade. Sci Rep 2019;9:7046. [PMID: 31065015 DOI: 10.1038/s41598-019-43469-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chua CW, Choo SP. Targeted therapy in hepatocellular carcinoma. Int J Hepatol 2011;2011:348297. [PMID: 21994852 DOI: 10.4061/2011/348297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
21 Hasanzad M, Sarhangi N, Aghaei Meybodi HR, Nikfar S, Khatami F, Larijani B. Precision Medicine in Non Communicable Diseases. Int J Mol Cell Med 2019;8:1-18. [PMID: 32351905 DOI: 10.22088/IJMCM.BUMS.8.2.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. Eur J Med Chem 2016;108:495-504. [PMID: 26717201 DOI: 10.1016/j.ejmech.2015.12.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
23 Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80:550-560. [PMID: 20371362 DOI: 10.1016/j.bcp.2010.03.034] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 7.7] [Reference Citation Analysis]
24 Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 2008;14:6437-6441. [PMID: 19030192 DOI: 10.3748/wjg.14.6437] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
25 Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 2008;14:2983-98. [PMID: 18991714 DOI: 10.2174/138161208786404326] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
26 Rimassa L, Santoro A, Daniele B, Germano D, Gasbarrini A, Salvagni S, Masi G, Abbadessa G, Lamar M, Goldberg T, Porta C. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers. Tumori 2015;101:139-43. [PMID: 25838254 DOI: 10.5301/tj.5000217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
27 Wörns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:615-29. [PMID: 20374038 DOI: 10.1517/13543781003767418] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
28 Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15:285-292. [PMID: 20203173 DOI: 10.1634/theoncologist.2009-0316] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
29 Hoover AC, Strand GL, Nowicki PN, Anderson ME, Vermeer PD, Klingelhutz AJ, Bossler AD, Pottala JV, Hendriks WJ, Lee JH. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 2009;28:3960-70. [PMID: 19734941 DOI: 10.1038/onc.2009.251] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
30 Germano D, Tinessa V, Barletta E, Cannella L, Daniele B. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib. Drugs Aging 2013;30:887-92. [PMID: 24097332 DOI: 10.1007/s40266-013-0124-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
31 Cuevas MJ, Tieppo J, Marroni NP, Tuñón MJ, González-gallego J. Suppression of Amphiregulin/Epidermal Growth Factor Receptor Signals Contributes to the Protective Effects of Quercetin in Cirrhotic Rats. The Journal of Nutrition 2011;141:1299-305. [DOI: 10.3945/jn.111.140954] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
32 Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. Cancers (Basel) 2019;11:E1568. [PMID: 31618961 DOI: 10.3390/cancers11101568] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Mishani E, Hagooly A. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 2009;50:1199-202. [PMID: 19617320 DOI: 10.2967/jnumed.109.062117] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
34 Ye JY, Chan GC, Qiao L, Lian Q, Meng FY, Luo XQ, Khachigian LM, Ma M, Deng R, Chen JL, Chong BH, Yang M. Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway. Haematologica. 2010;95:1745-1753. [PMID: 20562316 DOI: 10.3324/haematol.2009.020958] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
35 Maass T, Thieringer FR, Mann A, Longerich T, Schirmacher P, Strand D, Hansen T, Galle PR, Teufel A, Kanzler S. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer. 2011;128:1259-1268. [PMID: 20506153 DOI: 10.1002/ijc.25469] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
36 Abbas M, Saeed F, Anjum FM, Afzaal M, Tufail T, Bashir MS, Ishtiaq A, Hussain S, Suleria HAR. Natural polyphenols: An overview. International Journal of Food Properties 2017;20:1689-99. [DOI: 10.1080/10942912.2016.1220393] [Cited by in Crossref: 169] [Cited by in F6Publishing: 41] [Article Influence: 33.8] [Reference Citation Analysis]
37 Advani SH. Targeting mTOR pathway: A new concept in cancer therapy. Indian J Med Paediatr Oncol. 2010;31:132-136. [PMID: 21584218 DOI: 10.4103/0971-5851.76197] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
38 Scanga A, Kowdley K, Kowdley K, Mccaughan G, Trautwein C. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma? Hepatology 2009;49:332-4. [DOI: 10.1002/hep.22756] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
39 Zeng W, Gouw AS, van den Heuvel MC, Zwiers PJ, Zondervan PE, Poppema S, Zhang N, Platteel I, de Jong KP, Molema G. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology. 2008;48:1517-1527. [PMID: 18924243 DOI: 10.1002/hep.22490] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
40 Butt SS, Khan K, Badshah Y, Rafiq M, Shabbir M. Evaluation of pro-apoptotic potential of taxifolin against liver cancer. PeerJ 2021;9:e11276. [PMID: 34113483 DOI: 10.7717/peerj.11276] [Reference Citation Analysis]
41 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-099-9711-7] [Reference Citation Analysis]
42 Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 2011;11:524-34. [PMID: 21258214 DOI: 10.4161/cbt.11.5.14677] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
43 Huynh H. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer. 2010;116:1315-1325. [PMID: 20101735 DOI: 10.1002/cncr.24863] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
44 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 137] [Article Influence: 23.7] [Reference Citation Analysis]
45 Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol. 2013;24:68-73. [PMID: 23176968 DOI: 10.1016/j.jvir.2012.08.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
46 Wang X, Ding J, Feng Y, Weng L, Zhao G, Xiang J, Zhang M, Xing D. Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides. Oncol Lett 2017;13:1509-17. [PMID: 28454283 DOI: 10.3892/ol.2017.5602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
47 Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol. 2012;18:6005-6017. [PMID: 23155330 DOI: 10.3748/wjg.v18.i42.6005] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
48 Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62. [PMID: 19707376 DOI: 10.2147/btt.s3254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
49 Meguro M, Mizuguchi T, Kawamoto M, Hirata K. The molecular pathogenesis and clinical implications of hepatocellular carcinoma. Int J Hepatol 2011;2011:818672. [PMID: 22187659 DOI: 10.4061/2011/818672] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
50 Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goñi S, Santamaría M, Prieto J, Avila MA. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009;234:713-25. [PMID: 19429859 DOI: 10.3181/0901-MR-12] [Cited by in Crossref: 88] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
51 Vauzour D, Rodriguez-Mateos A, Corona G, Oruna-Concha MJ, Spencer JP. Polyphenols and human health: prevention of disease and mechanisms of action. Nutrients 2010;2:1106-31. [PMID: 22254000 DOI: 10.3390/nu2111106] [Cited by in Crossref: 422] [Cited by in F6Publishing: 307] [Article Influence: 38.4] [Reference Citation Analysis]
52 Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl 2009;15:169-76. [PMID: 19177438 DOI: 10.1002/lt.21678] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
53 Van Beers BE, Vilgrain V. Biomarkers in abdominal imaging. Abdom Imaging 2009;34:663-7. [DOI: 10.1007/s00261-008-9480-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
54 Zhu J, Wang Y, Yu Y, Wang Z, Zhu T, Xu X, Liu H, Hawke D, Zhou D, Li Y. Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues. Liver Int 2014;34:147-60. [PMID: 23902602 DOI: 10.1111/liv.12265] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
55 Li Z, Tang M, Ling B, Liu S, Zheng Y, Nie C, Yuan Z, Zhou L, Guo G, Tong A. Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma. J Mol Med (Berl). 2014;92:291-303. [PMID: 24281831 DOI: 10.1007/s00109-013-1104-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
56 Germano D, Daniele B. Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol 2014;20:3087-99. [PMID: 24696596 DOI: 10.3748/wjg.v20.i12.3087] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
57 Wilczynski J, Duechler M, Czyz M. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I. Arch Immunol Ther Exp (Warsz). 2011;59:289-299. [PMID: 21625848 DOI: 10.1007/s00005-011-0131-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
58 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7] [Cited by in Crossref: 948] [Cited by in F6Publishing: 764] [Article Influence: 79.0] [Reference Citation Analysis]
59 Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 2018;94:329-39. [PMID: 29719302 DOI: 10.1159/000485384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
60 Montella L, Addeo R, Caraglia M, Del Prete S. Latest developments in targeted therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2010;10:1635-1646. [PMID: 20942634 DOI: 10.1586/era.10.146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
61 Shi JH, Huitfeldt HS, Suo ZH, Line PD. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl. 2011;17:866-874. [PMID: 21542129 DOI: 10.1002/lt.22325] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
62 Li X, Dai D, Song X, Liu J, Zhu L, Xu W. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2014;38:583-591. [PMID: 24924902 DOI: 10.1016/j.clinre.2014.04.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
63 Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012;2:74-83. [PMID: 24175199 DOI: 10.5500/wjt.v2.i5.74] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
64 Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
65 Shi JH, Liu SZ, Wierød L, Scholz H, Anmarkrud JA, Huitfeldt HS, Zhang SJ, Line PD. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver. J Surg Oncol. 2013;107:393-401. [PMID: 22927239 DOI: 10.1002/jso.23224] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
66 Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 2016;46:391-406. [PMID: 26490438 DOI: 10.1111/hepr.12606] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
67 Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol. 2010;15:242-255. [PMID: 20509038 DOI: 10.1007/s10147-010-0089-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
68 Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008;12:2189-204. [PMID: 19120703 DOI: 10.1111/j.1582-4934.2008.00533.x] [Cited by in Crossref: 182] [Cited by in F6Publishing: 176] [Article Influence: 15.2] [Reference Citation Analysis]